{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-319981","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2025-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.648415+00:00","generated_at":"2026-05-16T13:05:22.359235+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MRT-2359 + enzalutamide shows 100% PSA response in AR-mutant mCRPC; Phase 2 planned 2026","bullets":["In 14 evaluable mCRPC patients, overall DCR 64% (9/14); in AR-mutant subset (n=4), 100% PSA response rate and 100% DCR, with 2 RECIST partial responses.","Combination well tolerated with primarily Grade 1-2 GI adverse events; no new safety signals.","Company plans to initiate Phase 2 study of MRT-2359 + AR inhibitor targeting AR-mutant mCRPC patients in 2026.","Breast cancer cohort (n=6) discontinued due to insufficient activity; MRT-8102 interim Phase 1 data expected early 2026.","Updated MRT-2359 data to be presented at ASCO GU Symposium in February 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-319981","json":"https://secwatch.observer/filing/0001193125-25-319981.json","markdown":"https://secwatch.observer/filing/0001193125-25-319981.md","text":"https://secwatch.observer/filing/0001193125-25-319981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000119312525319981/0001193125-25-319981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000119312525319981/glue-20251216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:05:22.359235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}